{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:14:20Z","timestamp":1780658060917,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1053\/j.seminoncol.2022.01.008","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T08:09:19Z","timestamp":1642666159000},"page":"48-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Daratumumab: A review of current indications and future directions"],"prefix":"10.1053","volume":"49","author":[{"given":"Elizabeth","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candis","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2022.01.008_bib0001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.beha.2020.101143","article-title":"Monoclonal antibodies in multiple myeloma. Current and emerging targets and mechanisms of action","volume":"33","author":"Wudhikarn","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.leukres.2003.09.015","article-title":"Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients","volume":"28","author":"Santonocito","year":"2004","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0003","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/0008-5472.CAN-14-3639","article-title":"CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer","volume":"75","author":"Karakasheva","year":"2015","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.008_bib0005","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/cells8121527","article-title":"CD38, a receptor with multifunctional activities: From modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies","volume":"8","author":"Morandi","year":"2019","journal-title":"Cells"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/5738371","article-title":"Lymphocytes in placental tissues: immune regulation and translational possibilities for immunotherapy","volume":"2017","author":"Erkers","year":"2017","journal-title":"Stem Cells Int"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0007","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/blood.V92.4.1324","article-title":"Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses","volume":"92","author":"Cockayne","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0008","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.V77.6.1218.1218","article-title":"Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells","volume":"77","author":"Terstappen","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.imlet.2018.11.007","article-title":"Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma","volume":"205","author":"Horenstein","year":"2019","journal-title":"Immunol Lett"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0011","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1074\/jbc.274.4.1869","article-title":"CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion","volume":"274","author":"Kato","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0012","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4049\/jimmunol.1500591","article-title":"CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation","volume":"195","author":"Morandi","year":"2015","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0013","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0014","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0015","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbcan.2014.08.001","article-title":"Cellular immunotherapy in multiple myeloma: Lessons from preclinical models","volume":"1846","author":"Binsfeld","year":"2014","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0016","first-page":"384","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood Am J Hematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0017","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0018","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"van der Veer","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0019","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"issue":"21","key":"10.1053\/j.seminoncol.2022.01.008_bib0021","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood.V120.21.2974.2974","article-title":"Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking","volume":"120","author":"Jansen","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0022","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0023","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0024","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s12325-018-0815-9","article-title":"Pharmacokinetics and exposure-response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma","volume":"35","author":"Xu","year":"2018","journal-title":"Adv Ther"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0026","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0028","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0029","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0030","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0031","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0032","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0033","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0034","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0035","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0036","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0037","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0038","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0039","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40265-016-0573-4","article-title":"Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma","volume":"76","author":"Moreau","year":"2016","journal-title":"Drugs"},{"issue":"19 Suppl: Abstract\u00a0nr","key":"10.1053\/j.seminoncol.2022.01.008_bib0040","first-page":"2563","article-title":"Development of clinical assay to mitigate daratumumab, an IgG1\u03ba monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma. [abstract]","volume":"74","author":"Axel","year":"2014","journal-title":"In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0041","doi-asserted-by":"crossref","first-page":"8590","DOI":"10.1200\/jco.2015.33.15_suppl.8590","article-title":"Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody","volume":"33","author":"McCudden","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0042","unstructured":"Immunofixation, Daratumumab-Specific, Serum. 2020. at Accessed from: https:\/\/www.labcorp.com\/tests\/123218\/immunofixation-daratumumab-specific-serum. Accessed at October 1st 2020."},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0043","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","article-title":"A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference","volume":"132","author":"Mills","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0044","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0045","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.V126.23.1829.1829","article-title":"Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius)","volume":"126","author":"Voorhees","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0046","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","article-title":"A recombinant human enzyme for enhanced interstitial transport of therapeutics","volume":"114","author":"Bookbinder","year":"2006","journal-title":"J Control Release"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0047","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0048","first-page":"959","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood, Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.008_bib0049","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0050","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0051","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0052","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2141.2007.06729.x","article-title":"Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma","volume":"138","author":"Rendtlew Danielsen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0053","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"The Lancet"},{"issue":"10292","key":"10.1053\/j.seminoncol.2022.01.008_bib0081","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0054","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1\u20132a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2018-153","article-title":"MOR202 with low-dose dexamethasone (Dex) or pomalidomide\/Dex or lenalidomide\/Dex in relapsed or refractory multiple myeloma (RRMM): primary analysis of a phase I\/IIA, multicenter, dose-escalation study","volume":"132","author":"Raab","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0056","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(19)30254-6","article-title":"Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?","volume":"7","author":"D'Agostino","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0057","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/blood-2019-128007","article-title":"Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Krishnan","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0058","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4049\/jimmunol.198.Supp.224.20","article-title":"TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion","volume":"198","author":"Smithson","year":"2017","journal-title":"J. Immunol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0059","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.119.256602","article-title":"A reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys","volume":"370","author":"Korver","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.008_bib0060","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0061","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0062","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0063","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0064","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0066","first-page":"938","article-title":"Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN","volume":"138","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.008_bib0067","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0082","first-page":"JCO2101935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","author":"Costa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0083","unstructured":"NCCN Guidelines Version 4.2022, Multiple Myeloma, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed 1.22.2022."},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0068","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.008_bib0069","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","article-title":"Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: A multicentric retrospective study and review of the literature","volume":"27","author":"Lecumberri","year":"2020","journal-title":"Amyloid"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0070","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.008_bib0071","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0084","unstructured":"JANSSEN BIOTECH. DARZALEX+Faspro (daratumumab and hyaluronidase-fihj)[package insert]. U.S. food and drug administration. Accessed from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX+Faspro-pi.pdf Accessed at: January 20, 2022."},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0072","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.13343","article-title":"Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab","volume":"104","author":"Salas","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0073","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1806295","article-title":"Daratumumab in primary effusion lymphoma","volume":"379","author":"Shah","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0074","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/bjh.15515","article-title":"Targeting CD38 with daratumumab is lethal to Waldenstrom macroglobulinaemia cells","volume":"183","author":"Paulus","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.008_bib0075","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04063-w","article-title":"Daratumumab for refractory warm autoimmune hemolytic anemia","volume":"100","author":"Jain","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0076","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Advances"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0077","first-page":"995","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood, Am J Hematol"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0078","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.clml.2019.12.022","article-title":"Daratumumab-based regimen in treating clonal plasma cell neoplasms in solid organ transplant recipients","volume":"20","author":"Chaulagain","year":"2020","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100022","article-title":"CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients","volume":"2","author":"Frerichs","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"10.1053\/j.seminoncol.2022.01.008_bib0080","unstructured":"JANSSEN BIOTECH. DARZALEX (daratumumab)[package insert]. U.S. food and drug administration. Accessed from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761036s029lbl.pdf. Accessed at: November 12, 2020."}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:56:51Z","timestamp":1758805011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775422000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0093775422000082"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.008","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab: A review of current indications and future directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}